Questions
Kisspeptin questions, answered straight from the research
Twenty-two of the most-asked questions, each with a direct answer and a citation where a number is involved.
How does kisspeptin work in the body?
Kisspeptin binds the KISS1R (GPR54) receptor on hypothalamic GnRH neurons and makes them fire, releasing GnRH in pulses; GnRH then drives LH and FSH from the pituitary, which act on the gonads. Loss-of-function GPR54 mutations cause failure of puberty in humans and mice, which established the pathway as essential [1].
Does kisspeptin regulate food intake and metabolism?
Kisspeptin neurons sense the body's energy state and relay it to the reproductive axis through leptin: leptin deficiency and diet-induced obesity both reduced hypothalamic kisspeptin in mice [8]. But in women with overweight or obesity, kisspeptin raised LH without changing hunger or food intake [10] — so it links metabolism to fertility without directly controlling appetite.
Is kisspeptin effective for weight management?
No. Despite the metabolism link, a controlled human study found that intravenous kisspeptin changed neither self-rated hunger nor objectively measured food intake in women with overweight or obesity, even though it confirmed biological activity by raising LH [10]. On current evidence, kisspeptin is not a weight-management agent.
Does kisspeptin affect bone metabolism?
An acute signal exists. In 26 healthy men, a 90-minute kisspeptin infusion (1 nmol/kg/h) raised bone-formation markers, with a 20.3% maximal rise in total osteocalcin and a 24.3% rise in carboxylated osteocalcin [11]. This suggests a possible direct skeletal action, but it is a single acute study, not evidence of a treatment effect.
What is kisspeptin?
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene that act as the principal upstream activators of GnRH neurons, making them the master regulator of the reproductive (HPG) axis. Loss-of-function mutations in its receptor cause failure of puberty [1]. It is an investigational research peptide, not an approved drug or a dietary supplement.
What does kisspeptin do?
Kisspeptin switches on the reproductive axis. By activating KISS1R on GnRH neurons, it triggers pulsatile GnRH release, which drives LH and FSH and, in turn, the sex steroids. Its essential role was proven by GPR54 loss-of-function mutations, which block puberty in both humans and mice [1].
Does kisspeptin increase testosterone?
Indirectly, yes, by raising LH. In healthy men, a continuous kisspeptin-10 infusion at 4 ug/kg/h raised serum testosterone from 16.6 to 24.0 nmol/L [3]. The rise is downstream of LH and modest — kisspeptin does not supply testosterone directly, and the effect is smaller than testosterone replacement.
How much does kisspeptin increase testosterone?
In the published study, a continuous intravenous kisspeptin-10 infusion at 4 ug/kg/h raised testosterone from 16.6 to 24.0 nmol/L in healthy men — about a 45% increase — secondary to a roughly three-fold LH rise [3]. This is a research finding at a defined dose and route, not a treatment outcome or a dosing recommendation.
What is kisspeptin used for in research?
Kisspeptin is studied for IVF oocyte-maturation triggering, restoring cycles in hypothalamic amenorrhea, probing the brain circuitry of sexual desire, and as a pregnancy biomarker. A 2025 systematic review counted 29 interventional trials across these and other applications, all investigational with no approved product [7].
Can kisspeptin help with fertility?
In research, yes, in specific settings. A Phase 2 trial used subcutaneous kisspeptin-54 (3.2-12.8 nmol/kg) to trigger oocyte maturation in 95% of women at high OHSS risk, with no OHSS and a 62% live-birth rate at the best dose [5]. It is an investigational trigger, not an approved fertility treatment.
Can kisspeptin restore ovulation in women with hypothalamic amenorrhea?
It restores the underlying hormone rhythm. A continuous kisspeptin-54 infusion (0.01-1.00 nmol/kg/h) raised LH pulses from 1.6 to 5.0 per 8 hours and increased pulse secretory mass about six-fold versus vehicle in affected women [4]. The highest dose, however, produced tachyphylaxis — the response faded during the infusion [4].
What is the difference between kisspeptin-10 and kisspeptin-54?
Both are active isoforms sharing the same receptor-binding tail, but they differ in size and duration. Kisspeptin-10 is the short ten-amino-acid fragment with a half-life of about 4 minutes; kisspeptin-54 is the long 54-amino-acid form (originally metastin) lasting about 27-28 minutes, owing to its size and resistance to enzyme breakdown [3][4].
What is the KISS1 gene?
KISS1 is the gene on chromosome 1q32 that encodes the kisspeptin precursor, later cleaved into the active isoforms. It was first identified in 1996 as a metastasis-suppressor gene, then reframed in 2003 when GPR54 mutations were shown to block puberty, revealing the kisspeptin system as the master switch of reproduction [1].
What is metastin and how does it relate to kisspeptin?
Metastin is the original name for kisspeptin-54, given when KISS1 was identified as a metastasis-suppressor gene. The terms are now used interchangeably: metastin and kisspeptin-54 are the same 54-amino-acid molecule, which acts on KISS1R as part of the reproductive axis [1].
How was kisspeptin discovered?
KISS1 was discovered in 1996 as a metastasis-suppressor gene in human melanoma, named for Hershey, Pennsylvania. Its receptor GPR54 was matched around 2001, and in 2003 loss-of-function GPR54 mutations were shown to cause failure of puberty in humans and mice — reframing kisspeptin as the upstream regulator of reproduction [1].
What receptor does kisspeptin bind?
Kisspeptin binds KISS1R, formerly called GPR54 (also hOT7T175 / AXOR12), a Gq/11-coupled receptor on hypothalamic GnRH neurons. Loss-of-function mutations in this receptor cause hypogonadotropic hypogonadism and failure of puberty; gain-of-function mutations cause precocious puberty [1].
How long does kisspeptin take to work?
Quickly. In healthy men, an intravenous kisspeptin-10 bolus produced maximal LH stimulation by 30 minutes (LH 4.1 to 12.4 IU/L) [3], and intranasal kisspeptin-54 raised LH rapidly in a 2025 study [6]. The hormonal response is fast; whether a person subjectively feels anything is far less consistent.
What is the half-life of kisspeptin?
It depends on the isoform. Kisspeptin-10 has a functional half-life of about 4 minutes in humans, cleared quickly by plasma peptidases; kisspeptin-54 lasts longer at about 27-28 minutes [3][4]. The longer half-life of kisspeptin-54 gives it a substantially longer duration of action, which is why it is favored in many reproductive protocols.
What is the mechanism by which kisspeptin-10 exerts its effects?
Kisspeptin-10 binds KISS1R and triggers a phospholipase C / IP3 / intracellular-calcium cascade that closes potassium channels and opens cation channels, depolarizing GnRH neurons. In mouse neurons, 100 nM kisspeptin depolarized cells by about 6 mV and raised firing by roughly 87% [2]. The result is pulsatile GnRH release driving LH and FSH.
How does stress suppress kisspeptin and disrupt the reproductive axis?
Stress, low body weight, and heavy exercise suppress GnRH pulsatility, which is associated with reduced kisspeptin-neuron activity — the basis of hypothalamic amenorrhea. The link is reversible at the kisspeptin level: a kisspeptin-54 infusion restored LH pulsatility about three-fold in affected women, with pulse secretory mass up roughly six-fold [4].
How does kisspeptin reduce OHSS risk compared to hCG as an IVF trigger?
Kisspeptin works through the body's own GnRH neurons and clears quickly, producing the maturation surge without the prolonged stimulation that drives OHSS. In a Phase 2 trial, kisspeptin-54 matured oocytes in 95% of high-risk women with no moderate, severe, or critical OHSS at any dose [5] — the central argument for it as a safer trigger.
Can kisspeptin-54 trigger ovulation more safely than GnRH agonists in IVF?
The evidence supports a strong safety profile. Subcutaneous kisspeptin-54 (3.2-12.8 nmol/kg) triggered oocyte maturation in 95% of women at high OHSS risk with no moderate-to-critical OHSS, and the highest live-birth rate (62%) followed the 9.6 nmol/kg dose [5]. It remains an investigational trigger studied in controlled trials, not an approved protocol.